Heron Therapeutics announces increased net sales in first-quarter 2024 financial results
Click Here to Manage Email Alerts
Key takeaways:
- Heron Therapeutics announced increased net product sales in its first quarter of 2024 financial results.
- The company reported $34.7 million in net product sales for the quarter.
Heron Therapeutics Inc. announced increased net product sales in its first quarter of 2024 financial results, according to a company press release.
Heron Therapeutics reported $34.7 million in net product sales for the quarter, an increase from its reported $29.6 million in the first quarter of 2023. The company reported $5.5 million in net product sales for its acute care franchise and $29.2 million in net product sales for its oncology care franchise.
“We are extremely pleased with our ability to improve the financial efficiency of the business by growing revenues, improving margins and reducing expenses,” Craig Collard, CEO of Heron Therapeutics, said in the release. “We made tremendous progress this quarter by promptly training CrossLink sales representatives and integrating them into our commercial execution, while also training our own commercial team on the newly expanded label for Zynrelef.”
Read more about
Click Here to Manage Email Alerts